Long non‑coding RNA MCM3AP‑AS1 facilitates colorectal cancer progression by regulating the microRNA‑599/ARPP19 axis
- You Yu
- Suhe Lai
- Xiaochao Peng
Affiliations: Department of General Surgery, The Bishan Hospital of Chongqing, Chongqing 402760, P.R. China
- Published online on: January 24, 2021 https://doi.org/10.3892/ol.2021.12486
Copyright: © Yu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Colorectal cancer (CRC) is one of the most aggressive malignancies worldwide. Increasing evidence has indicated that microRNA (miR)‑599 is involved in the occurrence and development of different types of tumors, such as breast cancer and glioma. However, the role of miR‑599 in CRC remains unclear. Thus, the present study aimed to identify the regulatory mechanism of miR‑599 in CRC progression. Reverse transcription‑quantitative PCR was used to analyze the expression levels of MCM3AP‑AS1, miR‑599 and ARPP19, and Cell Counting Kit‑8 and Transwell assays were used to determine the cell proliferation and migration of CRC cells. In addition, a dual‑luciferase reporter assay was used to analyze the direct interaction between miR‑599 and MCM3AP‑AS1 or ARPP19. Reverse transcription‑quantitative PCR analysis demonstrated that miR‑599 expression decreased in patients with CRC and in CRC cell lines, while miR‑599 overexpression inhibited cell proliferation and migration abilities in vitro. MCM3AP‑AS1 was identified as a molecular sponge of miR‑599, and further investigation indicated that MCM3AP‑AS1 silencing inhibited cell proliferation and migration of the CRC cell lines. In addition, ARPP19 was identified as a target gene of miR‑599, and MCM3AP‑AS1‑knockdown decreased ARPP19 mRNA expression and increased miR‑599 expression. Furthermore, silencing ARPP19 inhibited the proliferation and migration of the CRC cell lines. The results also demonstrated that MCM3AP‑AS1 promoted CRC cell progression by regulating the miR‑599/ARPP19 axis. Taken together, the results of the present study suggest that MCM3AP‑AS1 may be a novel therapeutic target for patients with CRC.